Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients
Clinical trial NCT02843074 · COMPLETED
Trial details
- NCT number
- NCT02843074
- Sponsor
- SCRI Development Innovations, LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-09-21
- Primary completion
- 2021-07-27
- Enrollment
- 53
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.